ES2318123T3 - Procedimiento para tratar la ansiedad en sujetos de edad avanzada. - Google Patents
Procedimiento para tratar la ansiedad en sujetos de edad avanzada. Download PDFInfo
- Publication number
- ES2318123T3 ES2318123T3 ES03719604T ES03719604T ES2318123T3 ES 2318123 T3 ES2318123 T3 ES 2318123T3 ES 03719604 T ES03719604 T ES 03719604T ES 03719604 T ES03719604 T ES 03719604T ES 2318123 T3 ES2318123 T3 ES 2318123T3
- Authority
- ES
- Spain
- Prior art keywords
- baselineskip
- xaa
- ser
- thr
- asn
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Plant Substances (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37546202P | 2002-04-25 | 2002-04-25 | |
| US375462P | 2002-04-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2318123T3 true ES2318123T3 (es) | 2009-05-01 |
Family
ID=29270644
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES03719604T Expired - Lifetime ES2318123T3 (es) | 2002-04-25 | 2003-04-17 | Procedimiento para tratar la ansiedad en sujetos de edad avanzada. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20050129691A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1501531B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2005523335A (cg-RX-API-DMAC7.html) |
| AT (1) | ATE419871T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2003223474B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2483729A1 (cg-RX-API-DMAC7.html) |
| DE (1) | DE60325717D1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2318123T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2003090772A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003279216A1 (en) * | 2002-10-09 | 2004-05-04 | Rinat Neuroscience Corp. | Methods of treating alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof |
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| ES2344645T3 (es) | 2003-02-10 | 2010-09-02 | Applied Molecular Evolution, Inc. | Moleculas de union al abeta. |
| AU2005290250A1 (en) * | 2004-07-30 | 2006-04-06 | Rinat Neuroscience Corp. | Antibodies directed against amyloid-beta peptide and methods using same |
| US20060153772A1 (en) * | 2004-12-15 | 2006-07-13 | Wyeth | Contextual fear conditioning for predicting immunotherapeutic efficacy |
| PE20061323A1 (es) * | 2005-04-29 | 2007-02-09 | Rinat Neuroscience Corp | Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos |
| RU2442793C2 (ru) | 2005-11-30 | 2012-02-20 | Эбботт Лэборетриз | АНТИТЕЛА ПРОТИВ ГЛОБУЛОМЕРА Аβ, ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ЧАСТИ, СООТВЕТСТВУЮЩИЕ ГИБРИДОМЫ, НУКЛЕИНОВЫЕ КИСЛОТЫ, ВЕКТОРЫ, КЛЕТКИ-ХОЗЯЕВА, СПОСОБЫ ПОЛУЧЕНИЯ УКАЗАННЫХ АНТИТЕЛ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ АНТИТЕЛА, ПРИМЕНЕНИЯ УКАЗАННЫХ АНТИТЕЛ И СПОСОБЫ ИСПОЛЬЗОВАНИЯ УКАЗАННЫХ АНТИТЕЛ |
| PL1976877T5 (pl) | 2005-11-30 | 2017-09-29 | Abbvie Inc | Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania |
| NZ568012A (en) * | 2005-12-12 | 2012-07-27 | Ac Immune Sa | A beta 1-42 specific monoclonal antibodies with therapeutic properties |
| RU2498999C2 (ru) * | 2006-07-14 | 2013-11-20 | Ац Иммуне Са | Гуманизированное антитело к амилоиду бета |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| WO2008088983A1 (en) | 2007-01-18 | 2008-07-24 | Eli Lilly And Company | PEGYLATED Aβ FAB |
| US8895004B2 (en) | 2007-02-27 | 2014-11-25 | AbbVie Deutschland GmbH & Co. KG | Method for the treatment of amyloidoses |
| US20090232801A1 (en) * | 2007-05-30 | 2009-09-17 | Abbot Laboratories | Humanized Antibodies Which Bind To AB (1-42) Globulomer And Uses Thereof |
| US8613923B2 (en) | 2007-06-12 | 2013-12-24 | Ac Immune S.A. | Monoclonal antibody |
| HRP20150086T1 (xx) * | 2007-06-12 | 2015-02-27 | Ac Immune S.A. | Humanizirana antitijela za beta amiloid |
| US8048420B2 (en) * | 2007-06-12 | 2011-11-01 | Ac Immune S.A. | Monoclonal antibody |
| PL2238166T3 (pl) * | 2007-10-05 | 2014-07-31 | Genentech Inc | Zastosowanie przeciwciała anty-Beta amyloidowego w chorobach oczu |
| AU2008311366B2 (en) * | 2007-10-05 | 2015-03-12 | Ac Immune S.A. | Use of anti-amyloid beta antibody in ocular diseases |
| WO2011130377A2 (en) | 2010-04-15 | 2011-10-20 | Abbott Laboratories | Amyloid-beta binding proteins |
| US9221900B2 (en) | 2010-07-30 | 2015-12-29 | Ac Immune S.A. | Methods for identifying safe and functional humanized antibodies |
| US9062101B2 (en) | 2010-08-14 | 2015-06-23 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9206422D0 (en) * | 1992-03-24 | 1992-05-06 | Bolt Sarah L | Antibody preparation |
| US5766846A (en) * | 1992-07-10 | 1998-06-16 | Athena Neurosciences | Methods of screening for compounds which inhibit soluble β-amyloid peptide production |
| US5837672A (en) * | 1992-07-10 | 1998-11-17 | Athena Neurosciences, Inc. | Methods and compositions for the detection of soluble β-amyloid peptide |
| US7964192B1 (en) * | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
| JP5249482B2 (ja) * | 1999-06-16 | 2013-07-31 | ボストン・バイオメデイカル・リサーチ・インステイテユート | インビボのβ−アミロイドレベルの免疫学的制御 |
| EA006606B1 (ru) * | 2000-02-24 | 2006-02-24 | Вашингтон Юниверсити | Гуманизированное антитело и его фрагмент, взаимодействующие с бета-амилоидным пептидом, и способы их применения |
| US20020009445A1 (en) * | 2000-07-12 | 2002-01-24 | Yansheng Du | Human beta-amyloid antibody and use thereof for treatment of alzheimer's disease |
| US7166478B2 (en) * | 2002-03-12 | 2007-01-23 | Enzo Life Sciences, Inc., C/O Enzo Biochem, Inc. | Labeling reagents and labeled targets, target labeling processes and other processes for using same in nucleic acid determinations and analyses |
-
2003
- 2003-04-17 ES ES03719604T patent/ES2318123T3/es not_active Expired - Lifetime
- 2003-04-17 EP EP03719604A patent/EP1501531B1/en not_active Revoked
- 2003-04-17 JP JP2003587405A patent/JP2005523335A/ja not_active Ceased
- 2003-04-17 WO PCT/US2003/010473 patent/WO2003090772A1/en not_active Ceased
- 2003-04-17 AT AT03719604T patent/ATE419871T1/de not_active IP Right Cessation
- 2003-04-17 DE DE60325717T patent/DE60325717D1/de not_active Revoked
- 2003-04-17 AU AU2003223474A patent/AU2003223474B2/en not_active Ceased
- 2003-04-17 US US10/512,527 patent/US20050129691A1/en not_active Abandoned
- 2003-04-17 CA CA002483729A patent/CA2483729A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ATE419871T1 (de) | 2009-01-15 |
| WO2003090772A1 (en) | 2003-11-06 |
| CA2483729A1 (en) | 2003-11-06 |
| EP1501531A1 (en) | 2005-02-02 |
| AU2003223474B2 (en) | 2008-09-04 |
| US20050129691A1 (en) | 2005-06-16 |
| AU2003223474A1 (en) | 2003-11-10 |
| DE60325717D1 (de) | 2009-02-26 |
| EP1501531A4 (en) | 2006-02-15 |
| EP1501531B1 (en) | 2009-01-07 |
| JP2005523335A (ja) | 2005-08-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1501531B1 (en) | Method for treating anxiety in older subjects | |
| US20090074775A1 (en) | Use Of Anti-AB Antibody To Treat Traumatic Brain Injury | |
| US20040241164A1 (en) | Use of antibodies having high affinity for soluble ab to treat conditions and diseases related to ass | |
| US20060073149A1 (en) | Rapid improvement of cognition in condition related to abeta | |
| CN109071645A (zh) | 抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其使用方法 | |
| EA032675B1 (ru) | Способ и композиции для лечения болезни альцгеймера и других таупатий | |
| BRPI0108676B1 (pt) | anticorpos humanizados que sequestram peptídeo amilóide beta e seus usos no tratamento de condições caracterizadas por formação de placas amiloides, bem como composição farmacêutica que compreende os referidos anticorpos | |
| CN109847058A (zh) | 疫苗疗法 | |
| US20230391859A1 (en) | Anti-transthyretin antibodies and methods of use thereof | |
| US12145991B2 (en) | Therapeutic antibody fragments, methods of making, and methods of use | |
| EA032000B1 (ru) | Способы лечения демиелинизирующей периферической нейропатии, вызванной травмой | |
| US20220072101A1 (en) | Harnessing inflammation to treat neurodevelopmental disorders | |
| US20230241061A1 (en) | Methods and pharmaceutical compositions for the treatment of fgfr3-related cognitive deficit | |
| US11597765B2 (en) | Use of semaphorin-4D binding molecules for the treatment of Rett syndrome | |
| RU2844863C1 (ru) | Применение молекул, связывающих семафорин-4d, для лечения синдрома ретта | |
| US20210196799A1 (en) | Compositions for Use in the Treatment of Neurological Disease | |
| Jacob et al. | Neurophysiological Assessment of Brain Network Activity Involved in Cognitive Processing in Animal Models of Alzheimer’s Disease | |
| Argento | Effect of exposure to methylphenidate in early life on cocaine reward in adulthood: a possible role for netrin-1 receptors | |
| Spear | Altered Gastrointestinal Motility in Multiple Sclerosis | |
| Shohami et al. | Israel Society for Neuroscience (ISFN) Committee | |
| Seyfried et al. | ANA 2017 Program | |
| Washington | Production, accumulation and clearance of amyloid-beta after experimental traumatic brain injury | |
| AU2002327203A1 (en) | Use of anitbodies having high affinity for soluble ass to treat conditions and diseases related to ass |